Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease.
Journal: Hematology (Amsterdam, Netherlands)
Published:
Abstract
The appearance of hepatitis B surface antigen (HBsAg) in patients previously positive for antibody to this antigen (HBsAb) is called reverse seroconversion, a rare complication after hematopoietic stem cell transplantation (HSCT), which occurs almost exclusively after HSCT from an HBsAb-negative donor and the development of chronic graft-versus-host disease (CGVHD). However, we experienced a patient who developed reverse seroconversion 23 months after unrelated HSCT even in the absence of immunosuppressants use or CGVHD. Serum immunoglobulin level was persistently normal. Therefore, all HBsAb-positive recipients should be considered to be at risk for HBV reactivation, even in patients without any risk factors.
Authors
Kumi Oshima, Miki Sato, Shinya Okuda, Kiriko Terasako, Hideki Nakasone, Shinichi Kako, Rie Yamazaki, Yukie Tanaka, Aki Tanihara, Takakazu Higuchi, Junji Nishida, Ikuo Nakamura, Yukio Yoshida, Yoshinobu Kanda
Relevant Conditions